Lineage Cell Therapeutics, Inc. - LCTX
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | President and CEO | P | A | 15,000.0 | 1.625 | 24,375.0 | 255,516.0 | View | |
| Mar 06, 2026 | General Counsel and Secretary | A | A | 900,000.0 | 0.0 | 0.0 | 900,000.0 | View | |
| Mar 06, 2026 | Chief Financial Officer | A | A | 1,050,000.0 | 0.0 | 0.0 | 1,050,000.0 | View | |
| Mar 06, 2026 | President and CEO | A | A | 3,250,000.0 | 0.0 | 0.0 | 3,250,000.0 | View | |
| Feb 13, 2026 | President and CEO | M | D | 31,250.0 | 0.0 | 0.0 | 0.0 | View | |
| Feb 13, 2026 | President and CEO | F | D | 12,869.0 | 1.8 | 23,164.2 | 240,516.0 | View | |
| Feb 13, 2026 | President and CEO | M | A | 31,250.0 | — | — | 253,385.0 | View | |
| Feb 13, 2026 | General Counsel and Secretary | M | D | 6,075.0 | 0.0 | 0.0 | 0.0 | View | |
| Feb 13, 2026 | General Counsel and Secretary | F | D | 2,502.0 | 1.8 | 4,503.6 | 31,063.0 | View | |
| Feb 13, 2026 | General Counsel and Secretary | M | A | 6,075.0 | — | — | 33,565.0 | View | |
| Dec 19, 2025 | President and CEO | F | D | 334.0 | 1.68 | 561.12 | 222,135.0 | View | |
| Dec 19, 2025 | President and CEO | A | A | 8,925.0 | — | — | 222,469.0 | View | |
| Dec 19, 2025 | General Counsel and Secretary | F | D | 65.0 | 1.68 | 109.2 | 27,490.0 | View | |
| Dec 19, 2025 | General Counsel and Secretary | A | A | 1,735.0 | — | — | 27,555.0 | View |